[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620080":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":37,"centralContacts":43,"locations":49,"responsibleParty":70,"collaborators":37,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":37,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":81,"enrollmentInfo":82,"targetDuration":37,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":37,"overallStatus":91,"whyStopped":37,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},{"fullName":5,"class":6},"Innovent Biologics (Suzhou) Co. Ltd.","INDUSTRY",[8,14,17,20,25,28],{"label":9,"type":10,"description":11,"interventionNames":12},"IBI3016 dose 4","EXPERIMENTAL","subcutaneous injection",[13],"Drug: IBI3016",{"label":15,"type":10,"description":11,"interventionNames":16},"IBI3016 dose 1",[13],{"label":18,"type":10,"description":11,"interventionNames":19},"IBI3016 dose 2",[13],{"label":21,"type":22,"description":11,"interventionNames":23},"placebo","PLACEBO_COMPARATOR",[24],"Other: Placebo",{"label":26,"type":10,"description":11,"interventionNames":27},"IBI3016 dose 3",[13],{"label":29,"type":10,"description":11,"interventionNames":30},"IBI3016 dose 5",[13],[32,38],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","IBI3016","Solution of Injection",[15,18,26,9,29],null,{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":37},"OTHER","Placebo","0.9% sodium chloride saline solution",[21],[44],{"name":45,"role":46,"phone":47,"phoneExt":37,"email":48},"Jinling Fan","CONTACT","0512-69566088","jinling.fan@innoventbio.com",[50],{"facility":51,"status":37,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Beijing Anzhen Hospital, Capital Medical University","Beijing","Beijing Municipality","100029","China","CN",{"type":58,"coordinates":59},"Point",[60,61],116.39723,39.9075,{"lat":61,"lon":60},[64,68],{"name":65,"role":46,"phone":66,"phoneExt":37,"email":67},"Jun Cai","010-81992130","caijun7879@126.com",{"name":65,"role":69,"phone":37,"phoneExt":37,"email":37},"PRINCIPAL_INVESTIGATOR",{"type":71,"investigatorFullName":37,"investigatorTitle":37,"investigatorAffiliation":37,"oldNameTitle":37,"oldOrganization":37},"SPONSOR","100620080","phase-2-a-dose-finding-study-of-ibi3016-in-mild-to-moderate-hypertensive-patients-100620080",false,"NCT07352969","A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients","A Randomized, Double-blind, Placebo-controlled, Multicenter, 24 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of IBI3016 in Mild to Moderate Hypertensive Patients","Inclusion Criteria:\n\n1. Signed informed consent.\n2. Males or females aged 18 to 75 years.\n3. Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication\n4. Mean sitting SBP ≥140 mmHg and \\\u003C 170 mmHg measured by OBPM.\n5. Participants able to understand and comply with study procedures.\n\nExclusion Criteria:\n\n1. Known history of secondary hypertension.\n2. Orthostatic hypotension.\n3. Laboratory parameter assessments outside of range at screening：\n\n   * Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) \\> 2× Upper Limit of Normal (ULN)\n   * Total Bilirubin \\> 1.5× ULN\n   * International Normalized Ratio (INR) \\> 2.0\n   * Serum Potassium \\> 5 mg\u002FL\n   * Estimated Glomerular Filtration Rate (eGFR) ≤ 45 mL\u002Fmin\u002F1.73m²\n   * QTcF \\> 480 ms\n4. Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.\n5. Current or history of intolerance to ACEi and\u002For ARBs.\n6. Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening. Any history of congestive heart failure.\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply","ALL","18 Years","75 Years",{"count":83,"type":84},352,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension",[90],"Hypertension","NOT_YET_RECRUITING","2026-01-13",{"date":94,"type":95},"2026-01-20","ACTUAL",{"date":97,"type":84},"2026-02-06",{"date":99,"type":84},"2029-03-27",{"name":5,"class":6},1]